Quarterly report pursuant to Section 13 or 15(d)

Revenues

v3.23.2
Revenues
9 Months Ended
May 31, 2023
Revenues  
Revenues

10.  Revenues

 

A breakdown of our revenues by type for the nine-months ended May 31, 2023, and 2022 are as follows:

 

 

 

Nine-Months Ended May 31,

 

 

 

2023

 

 

2022

 

IP Licensing

 

$ 104,935

 

 

$ 16,160

 

B2B

 

 

44,167

 

 

 

111,597

 

Other

 

 

80,539

 

 

 

16,490

 

 

 

$ 229,641

 

 

$ 144,247

 

 

During the nine-month period ended May 31, 2023, the Company recognized licensing revenue consisting of IP licensing fees for transfer of the DehydraTECH technology in line with definitive agreements and includes royalty fees. B2B product revenues of $44,167 (2022 - $111,597) were recorded that relate to sales of our intermediate products for use by B2B customers in their products. The Company recognized $104,935 (2022 - $16,160) in licensing revenue in the same period.